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Abstract
The prevalence and inclination to chronization of viral hepatitis B is 3–5 times higher in patients with HIV-infection than in 
HIV-negative ones. The natural clinical course of chronic hepatitis B (CHB) in patients with HIV has the features, connected with 
immune suppression and mutual influence of viruses. The quantitative determination of HBsAg allows the more precise monitoring 
of the natural course and the dynamics of treatment of patients with CHB but these features are little studied in patients with co-in-
fection CHB/HIV. 
In the work was presented the comparative analysis of the results of quantitative determination of the serum HBsAg in 59 Pa-
tients with co-infection CHB/HIV and 60 ones with chronic hepatitis. At the study it was established, that in patients with CHB/HIV 
co-infection were observed the reliably higher qHBsAg levels than in HIV-negative ones both in whole and in each CHB phase that 
depends on the immune suppression degree and DNA level of hepatitis B virus. 
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hepatitis B virus, HIV-infection, CD4+ quantity.
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1. Introduction
The prevalence of chronic hepatitis B in the world is 350–400 million persons (according to 
WHO data, 1,49 for 100000 population). At the same time the prevalence in different countries is 
from 0,2 % to 20 % [1]. By CHB level, Ukraine relates to the moderately precinctive regions (the 
level of infection of population is 2–7 %) [1]. According to the estimated data, the number of hepa-
titis B virus carriers in Ukraine exceeds 1 mln persons (mass screening was not realized). 
HBV prevalence in the different groups of HIV-infected of European region, according to 
WHO data, among the injective drugs users (IDU) is 7–10 %, among men that have sex with men 
(MSM) – 9–17 %, among persons, infected with CHB/HIV by heterosexual way – 4–6 % [2].
The risk of chronization of acute HBV in HIV-negative persons is 5–10 %, whereas in 
HIV-positive ones and in patients with other types of immune suppression the risk is 3–5 times 
higher [3]. The qualitative determination of HBsAg is used for the screening of patients for reve-
lation of HBV infection. In further at the positive result it is recommended to undergo the series 
of serological (HBeAg, HBeIg, HBcorIg, HBsAgIg) and molecular-genetic (HBV-DNA) tests. The 
typical course of chronic hepatitis B is characterized with the presence of HBsAg, HBcor Ig to-
tal, presence or absence of HBeAg and different HBV-DNA level. Seroconversion is determined 
correspondingly at appearance of antibodies (Ig) to HBeAg and HBsAg in the blood, absence of 
antigens and HBV-DNA. 
The natural course of chronic hepatitis B is presented by three successive phases of dis-
ease: immunotolerant, phase of immune clearance (immunoactive) – replicative, phase of im-
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mune control (inactive carriage) – low-replicative/non-replicative. The fourth phase of reactivation 
(HBеAg-negative CHB) – replicative is also separated [4–7].
– immune tolerant phase (IT) is typical for the perinatal infection and can continue for sev-
eral decades of life, is attended by the high viremia and presence of HBеAg; 
– the phase of immune clearance (IC) is attended by the presence of HBеAg, relatively low 
level of virus, increase or fluctuation of aminotransferase level; 
– low-replicative phase (LR) – inactive carriage can be observed after seroconversion of 
HBеAg and the presence of antibodies to HBеAg. The very low HBV-DNA level is also typical, 
sometimes even lower than the level of determination, normal level of amin transferases in the 
blood serum; 
– the phase of reactivation (RA) – HBеAg-negative CHB can develop after seroconver-
sion of HBеAg (appearance of HBеIg) in immune active phase or after several years of carriage 
of inactive virus. Reactivation of HBV infection with development of HBeAg-negative CHB 
and sometimes with reversion of HBeAg and development of HBeAg-positive CHB is often 
observed in persons with immune suppression including HIV-infected ones [9]. This stage is in 
fact the late immune active phase in the natural development of CHB. It is characterized with 
fluctuation of HBV-DNA level and aminotransferases, presence of HBeIg, HBcor Ig, absence of 
HBsAg Ig [7] (Table 1). 
Table 1
The phases of development of chronic hepatitis B [13, 14]
Phase HBeAgаnti-HBe HBsAg HBV-DNA level ALT level Level of histological changes in liver 
“IT”
HBeAg “+” 
аnti-HBe “–”
“+”
>1×106 IU/ml [13]
>2×105 IU/ml [14] norm Minimal inflammation and fibrosis 
“IC”
HBeAg “+”  
аnti-HBe “+”
“+”
>2×104 IU /ml [13]
>2×103IU/ml [14] increased Inflammation and fibrosis of middle and hard degree 
“NR” 
HBeAg “–” 
аnti-HBe “+”
“+”
<2×103 IU/ml
[13, 14]
norm Minimal activity of inflammation and variable fibrosis 
“RA”
HBeAg “–” 
аnti-HBe “+”
“+”
>2×103 UI/ml [13] 
>2×104 UI/ml [14] increased Inflammation and fibrosis of middle and hard degree 
There are studies that state that in HBV carriers HBsAg level in the blood serum was 
<1000 IU/ml [8].
Thus serological markers, HBV-DNA level, the levels of transaminases and histological 
changes in the liver are often used for determination of phase of CHB natural course. But last years 
the active role is given to the quantitative determination of HBsAg for differentiation of phases 
of CHB natural course [10–12, 19–21]. According to the literary data, the reliable difference in 
HBsAg levels is observed in patients with CHB mono-infection. qHBsАg is also used for the prog-
nosis of CHB reactivation. But this question is insufficiently studied for the specific population of 
patients, namely the ones with HIV/CHB co-infection and the factors that influence qHBsАg in 
co-infected patients are not sufficiently studied too. 
2. Aim of research
To study the changes of HBsAg concentration at the different phases of CHB natural course 
in HIV-infected patients. To determine the factors that influence qHBsAg.
3. Materials and methods
59 patients with HIV/CHB co-infection (main group) and 60 patients with CHB mono- 
infection (control group) were under observation. The main group included 21 women (35,6 %) and 
38 men (64,5 %) – mean ageт 35,6±1,1 years. The control group included 25 women (41,7 %) and 
35 men (58,3 %) – mean age 33,9±1,6 years. 
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All patients were under ambulatory observation in Vinnitsa city hepatological center of 
City clinical hospital № 1 and MI “Vinnitsa regional center of prophylaxis and fight against 
AIDS” in 2013–2016.
For distinction of phases of CHB natural course was used determination of HBV markers 
(HBeAg, HBe Ig, HBcor Ig, HBsAg Ig), HBV-DNA, alanine aminotransferase (ALT) level, APRI 
non-invasive method of determination of  fibrosis degree and also quantitative determination of 
HBsAg. All observed patients did not receive anti-viral therapy. 
Statistical processing of the received results was carried out using the program package 
“STATUSTICA 5,5”, license № AXXR910A374605FA.“”
4. Experimental procedures
The laboratory studies included: determination of HBV serological markers, quantitative 
determination of HBsAg (IU/ml), quantitative determination of HBV-DNA (IU/ml), level of al-
anine aminotransferase (ALT) (Un/l), level of CD4+ (cells/µl). Serological markers were deter-
mined by the method of immune-enzyme analysis (IEA) using spectrophotometer “Sanrise RC”. 
Quantitative determination of HBsAg in the blood serum was carried out by the method of immu-
nocheminuminescence using test-system “HBsAg Architect Kit (6C36)” by “Abbott Laboratories” 
using automatic analyzer “Architect” (sensitivity – 0,05 IU/ml). Determination of HBV-DNA was 
carried out by PCR using test-systems “AmpliSense® HBV-FL” using PCR system in the real time 
Bio-Rad iQ-5 (sensitivity – 50 IU/ml). Determination of ALT activity was carried out by kinetic 
method using automatic biochemical analyzer Vitalab Flexor (referential value – up to 41 Un/l). 
CD4+ level was determined by the method of running cytometry using the running cytometer 
EPICS-XL (diapason of determination from 1 cells/µl and more, size of cells 1–40 mcm).
5. Results
The most patients with CHB mono-infection (control group) were in age diapasons 20–29 
and 30–39 years that is 76,6 % of patients of the group. At the same time the age diapasons of most 
patients with co-infection CHB/HIV are a bit displaced to 30–39 and 40–49 years – together 67,8 % 
of patients of the group (Fig. 1).
Fig. 1. Distribution of patients with CHB-mono-infection (n=60) CHB/HIV  
co-infection (n=59) in age groups
For comparing the levels of HBsAg serum concentrations in patients in the different phases 
of natural course, patients were divided in 3 subgroups, according to aforesaid criteria. The phase 
of “immune clearance” – 6 patients (3 – main, 3 – control), phase of “HBeAg-negative reactiva-
tion” – 42 patients (17 – main, 25 – control), “low-replicative phase” – 71 patient (39 – main, 
32 – control). The immunotolerant phase was not present in any studied group (Тable 2).
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Table 2
qHBsAg (IU/ml)/(log10IU/ml)levels in the blood serum of patients with CHB/HIV co-infection depending 
on CHB phase  
Phase of disease
CHB/HIV(main) n=59 CHB (control) n=60 p
HBsAg, IU/ml/(log10 IU/ml)
Phase of  immune  
clearance (IC) – “HBeAg+”, n=6
(n=3) * 55195,9±28861,3
(4,74±4,46)
(n=3) * 40970,4±23688,3
(4,61±4,37) р=0,55
Phase of 
reactivation (RA) – “HBeAg-”, n=42 
(n=17)* 26375,2±7328,7
(4,42±3,86)
(n=25)* 11222,0±2046,3
(4,05±3,31) р <0,001
Low-replicative phase (LR), n=71
(n=39)* 4401,8±1062,0
(3,64±3,03)
(n=32)* 2631,2±615,6
(3,42±2,79)
р <0,001
Note: * – р <0,05 – between IC, RA and LR phases within the main and control groups; р <0,05 – reliable difference between the 
groups of comparison
Thus the received results testify to the reliable differences of HBsAg serum concentrations 
level between patients with CHB/HIV co-infection and CHV-infection (р <0,001), except patients 
with HBeAg-positive hepatitis in the phase of immune clearance where the difference was not 
reliable, р=0,55. 
At comparison of the phases of chronic hepatitis B course the received values of qHBsAg 
IU/ml) results were also converted in log10 IU/ml for more effectiveness. As a result of comparison 
it was discovered that in the group of CHB/HIV co-infected persons HBsAg serum concentration 
was higher in IC phase comparing with RA by 0,32 log10 IU/ml, in RA phase comparing with LR 
by 0,78 log10 IU/ml and also in IC phase comparing with LR by 1,1 log10 IU/ml. The same situation 
is also in the group of CHB-infected patients: qHBsAg is higher in IC phase comparing with RA 
by 0,56 log10 IU/ml, in RA phase comparing with LR by 0,63 log10 IU/ml and also in IC phase 
comparing with LR by 1,19 log10 IU/ml. The essential difference of qHBsAg mean values (р<0,05) 
was also received within each group.
For explanation of the received reliable differences between qHBsAg of the main and 
control group and determination of factors that influence HBsAg concentration in patients 
with CHB/HIV co-infection, the analysis of qHBsAg was carried out depending on CD4+ and 
HBV-DNA level. For assessment of the influence of CD4+ level on HBsAg serum concentra-
tion, CHB/HIV co-infected patients were divided in three subgroups with distinctive points 
CD4+ 350 cells/µl and 500 cells/µl (Table 3).
Table 3
qHBsAg(IU/ml)/(log10 IU/ml) levels in the blood serum of patients with CHB/HIV co-infection depending 
on CD4+ quantity (cells/µl)
Phase of disease 
CD4+<350 cells/µl p CD4+ 350–500 cells/µl p CD4+>500 cells/µl
HBsAg, IU/ml/(log10 IU/ml)
Phase of immune clearance (IC), 
“HBeAg+”, n=3 – – – –
(n=3) 55195,9±28861,3
(4,74±4,46)
Phase of reactivation (RA), 
“HBeAg-”, n=17
(n=9) 
47842,9±20945,3
(4,67±4,32)
p<0,05
(n=3) 17697,9±4152,7
(4,24±3,62) р=0,9
(n=5) 17341,1±5853,2
(4,23±3,77)
Low-replicative phase (LR), n=39
(n=11) 
6773,3±2866,2
(3,83±3,46)
p<0,05
(n=13) 4190,7±1315,9
(3,62±3,12) p<0,05
(n=15) 2845,7±1378,4
(3,45±3,14)
Note: р <0,05 – reliable difference between the groups of comparison
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The analysis of qHBsAg in patients in IC phase was not carried out because of the presence 
of patients only in subgroup with CD4+ level> 500 cells/µl. The received results testify to the influ-
ence of CD4+ level on HBsAg serum concentrations, especially at significant immune suppression 
(СD4+ <350 cells/µl). At analysis of patients in the phase of reactivation it was revealed, that in 
patients with CD4+<350 cells/µl qHBsAg was by 0,44 log10 IU/ml more than with CD4+ lev-
el >500 cells/µl (р<0,05). The reliable difference (р=0,9) is absent between subgroups of patients 
with CD4+350–500 cells/µl and >500 cells/µl of RA phase. Among patients of low-replicative 
phase was traced the reliable difference by 0,38 log10 IU/ml between the extreme CD4+ subgroups 
of patients (р<0,05).
HBV-DNA parameter 2×103 IU/ml was chosen for distinction of subgroups of patients be-
cause just this parameter is applied as one of the factors of determination of phases of chronic 
hepatitis B course [13, 14] (Table 4). 
Table 4
qHBsAg(IU/ml)/(log10 IU/ml) levels in the blood serum of patients with CHB/HIV co-infection depending 
on HBV-DNA level
Phase of disease 
HBV-DNA <2×103  IU/ml р HBV-DNA >2×103 IU/ml
HBsAg, IU/ml/(log10 IU/ml)
Phase of immune clearance (IC) – “HBeAg+”, n=3 – –
(n=3) 55195,9±28861,3
(4,74±4,46)
Phase of reactivation (RA) – “HBeAg-”, n=17
(n=4) 
22825,4±8782,9
(4,36±3,94)
р <0,05
(n=13) 
37912,1±12513,5
(4,58±4,10)
Low-replicative phase (LR), n=39
(n=28) 3068,0±1204,4
(3,49±3,09)
р <0,001
(n=11) 7797,0±1902,9
(3,90±3,30)
Having carried out the comparison in subgroups with HBV-DNA level more/less 2×103 IU/ml 
was revealed the reliable difference in both phase of reactivation by 0,22 log10 IU/ml (р<0,05) and in 
low-replicative phase by 0,49 log10 IU/ml (р<0,001). 
6. Discussion
Taking into account the large number of works, devoted to the mutual connection of 
qHBsAg and the phases of CHB natural course in HIV-negative patients [8, 10–12, 17], in 
this research was realized the comparative analysis of the results of quantitative determi-
nation of HBsAg in HIV-positive and HIV-negative patients in the different phases of CHB 
natural course. The received qHBsAg results that characterize the “phase of reactivation of 
HBeAg-negative CHB” and “low-replicative phase” demonstrated the reliably more HBsAg 
serum concentrations in CHB/HIV co-infected patients comparing with ones of the control 
group (р<0,001). In the phase of “immune clearance” the reliable difference between the main 
and control group was not observed that was probably limited by the number of patients related 
to this group (р=0,55). At the same time in CHB/HIV co-infected patients the most HBsAg 
serum concentration was observed in IC phase and the least one – in LR phase with the differ-
ence 1,1 log10 IU/ml (р <0,001).
The existent studies showed the influence of CD4+ level, presence of HBV-DNA on HBsAg 
serum concentration [15, 16, 18].
The received results also testify to the influence of immune suppression (СD4+ <350 cells/µl) 
on the increase of HBsAg serum concentrations in both “phase of reactivation of HBeAg-negative 
CHB” and “low-replicative phase” (р <0,05). The lowest HBsAg serum concentration is in persons 
with CD4+ level>500 cells/µl (р <0,05)
After determination of HBV in the group of patients with CHB/HIV co-infection it was also 
elucidated, that among persons with HBV-DNA level >2000 IU/ml the mean index of serum
Original Research Article:
full paper
(2016), «EUREKA: Health Sciences»
Number 6
28
Medicine and Dentistry
HBsAg was reliably higher comparing with patients with HBV-DNA<2000 IU/ml in both RA 
phase (р<0,05) and LR phase (р<0,001). These results are comparable with the literary sources [15, 16]. 
7. Conclusions
1. Thus in patients with CHB/HIV co-infection is observed the reliably higher qHBsAg 
levels than in HIV-negative patients in whole and in each separate phase of CHB. 
2. The quantities of CD4+, HBV-DNA are the node factors, reliably connected and influenc-
ing HBsAg serum concentration in CHB/HIV co-infected patients. 
3. Based on the received results it would be expedient the early (CD4+>500 cells/µl) pre-
scription of nucleos inhibitors of reverse transcriptase with double activity that allows receive the 
effective immune response to the treatment of both HIV-infection and chronic hepatitis B and also 
avoid the development of syndrome of renewal of immune system and aggravation of the chronic 
disease of the liver, connected with HBV. 
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